# Neuroinflammation as a Central Mechanism in Alzheimer’s Disease: Therapeutic Insights from Schiff Base Derivatives

## TL;DR

This paper explores how neuroinflammation contributes to Alzheimer’s disease and highlights the potential of Schiff base compounds as multi-target treatments.

## Contribution

The paper systematically reviews the multi-target therapeutic potential of metal-incorporated Schiff bases for Alzheimer’s disease.

## Key findings

- Neuroinflammation plays a central role in Alzheimer’s disease progression.
- Schiff bases show promise in modulating multiple pathological processes in Alzheimer’s disease.
- More comprehensive studies are needed to evaluate the pharmacokinetic profiles of these compounds.

## Abstract

Despite decades of intensive research, an effective cure for Alzheimer’s disease (AD) remains elusive. Although AD is classically linked to amyloid-beta (Aβ) aggregation, growing evidence highlights neuroinflammation as a major driver of disease progression. Neuroinflammation forms a self-amplifying cycle involving various factors such as cytokines, chemokines, oxidative stress, and glial cell activation, emphasizing the need for multi-target therapeutic strategies. Schiff bases have emerged as promising candidates, especially metal-incorporated Schiff bases, as numerous preclinical studies have demonstrated their ability to modulate key pathological processes, including inflammation, oxidative stress, reactive oxygen species (ROS) impairment, metal dysregulation, Aβ aggregation, and cholinergic dysfunction. Additionally, some preclinical studies even revealed the neuroprotective and anti-amnesic potential of Schiff bases. Nevertheless, these activities have been investigated across diverse structures of Schiff bases, and systematic evaluation of metal-incorporated Schiff bases remains limited. Although Schiff base-based anti-AD investigations have remained exclusively at the preclinical level, the huperzine A prodrug ZT-1 progressed to early-phase clinical trials before its development was discontinued. Comprehensive studies assessing their multi-target potential with their pharmacokinetic profiles are therefore essential to advance their development as prospective anti-AD agents.